Ilhan Gokhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ilhan Gokhan has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Stuart G. Campbell
Department of Biomedical Engineering, Yale University, New Haven, CT, USA
5 shared publications - Fadi G. Akar
Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine
2 shared publications - Jennifer M. Kwan
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA
2 shared publications - Jiun-Ruey Hu
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publications - Parul U. Gandhi
Section of Cardiovascular Medicine, Yale School of Medicine, Yale University, New Haven, CT 06520, USA
2 shared publications - Xia Li
Department of Biomedical Engineering (I.G., M.M., X.L., M.Z., J.M.S., F.G.A., S.G.C.), Yale University, New Haven, CT
2 shared publications
Latest Publications
- 25 September 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (8)
Desmoplakin Loss Leads to PKC- and Src-Mediated Contractile Dysfunction in Cardiomyocytes
BACKGROUND: Mutations in DSP , which encodes the protein desmoplakin, lead to cardiomyopathy with unusually high penetrance that presents with arrhythmias, fibro-fatty infiltration, and eventually heart failure. However, the precise mechanism of contractile dysfunction and dilation is incompletely understood. Here, we investigate the pathogenesis of DSP -R451G, a missense mutation that results in complete degradation of desmoplakin protein. METHODS: We use 3 complementary models to characterize desmoplakin-linked cardiomyopathy: induced pluripotent stem cell-derived engineered heart tissue expressing R451G desmoplakin, a heterozygous Dsp WT/R451G knock-in mouse, and left-ventricular biopsy specimens. Tissue-engineered constructs are used to characterize contractility, calcium handling, sarcomere length, and cell signaling. These results are corroborated in the R451G mouse. To expand the generalizability of the findings, we compare them to those from human heart biopsies bearing 4 different desmoplakin mutations. RESULTS: Using induced pluripotent stem cell-derived engineered heart tissue and isolated mouse ventricular cardiomyocytes, we recapitulate a disease phenotype consistent with desmoplakin cardiomyopathy and identify shortened resting sarcomere length as a pathogenic mechanism for contractile dysfunction. Phosphorylation of Src and protein kinase C underlies sarcomere shortening in mutant tissues, and pharmacological inhibition of these kinases rescues sarcomere length. Notably, these sarcomeric and biochemical hallmarks are also present in human hearts bearing different desmoplakin mutations. We next identify the redistribution of mechanical force at cardiomyocyte junctions as a proximal factor that may promote mechanoactivation of proto-oncogene tyrosine-protein kinase Src. Finally, we rescue sarcomere length and contractile function in DSP -mutant engineered heart tissue with dasatinib, a Food and Drug Administration-approved receptor tyrosine kinase inhibitor. CONCLUSIONS: Our study reveals a mechanism by which a desmosomal mutation affects cardiomyocyte function at the sarcomere level through activation of key signaling pathways that have not previously been implicated in desmoplakin cardiomyopathy.
- 25 September 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (8)
Desmoplakin Loss Leads to PKC- and Src-Mediated Contractile Dysfunction in Cardiomyocytes
BACKGROUND: Mutations in DSP , which encodes the protein desmoplakin, lead to cardiomyopathy with unusually high penetrance that presents with arrhythmias, fibro-fatty infiltration, and eventually heart failure. However, the precise mechanism of contractile dysfunction and dilation is incompletely understood. Here, we investigate the pathogenesis of DSP -R451G, a missense mutation that results in complete degradation of desmoplakin protein. METHODS: We use 3 complementary models to characterize desmoplakin-linked cardiomyopathy: induced pluripotent stem cell-derived engineered heart tissue expressing R451G desmoplakin, a heterozygous Dsp WT/R451G knock-in mouse, and left-ventricular biopsy specimens. Tissue-engineered constructs are used to characterize contractility, calcium handling, sarcomere length, and cell signaling. These results are corroborated in the R451G mouse. To expand the generalizability of the findings, we compare them to those from human heart biopsies bearing 4 different desmoplakin mutations. RESULTS: Using induced pluripotent stem cell-derived engineered heart tissue and isolated mouse ventricular cardiomyocytes, we recapitulate a disease phenotype consistent with desmoplakin cardiomyopathy and identify shortened resting sarcomere length as a pathogenic mechanism for contractile dysfunction. Phosphorylation of Src and protein kinase C underlies sarcomere shortening in mutant tissues, and pharmacological inhibition of these kinases rescues sarcomere length. Notably, these sarcomeric and biochemical hallmarks are also present in human hearts bearing different desmoplakin mutations. We next identify the redistribution of mechanical force at cardiomyocyte junctions as a proximal factor that may promote mechanoactivation of proto-oncogene tyrosine-protein kinase Src. Finally, we rescue sarcomere length and contractile function in DSP -mutant engineered heart tissue with dasatinib, a Food and Drug Administration-approved receptor tyrosine kinase inhibitor. CONCLUSIONS: Our study reveals a mechanism by which a desmosomal mutation affects cardiomyocyte function at the sarcomere level through activation of key signaling pathways that have not previously been implicated in desmoplakin cardiomyopathy.
- Open Access
- 1 June 2025
- Published by AIP Publishing in APL Bioengineering
- Vol. 9 (2) , 026124
Application of instant assembly of collagen to bioprint cardiac tissues
Advancing cardiac tissue engineering requires innovative fabrication techniques, including 3D bioprinting and tissue maturation, to enable the generation of new muscle for repairing or replacing damaged heart tissue. Recent advances in tissue engineering have highlighted the need for rapid, high-resolution bioprinting methods that preserve cell viability and maintain structural fidelity. Traditional collagen-based bioinks gel slowly, limiting their use in bioprinting. Here, we implement TRACE (tunable rapid assembly of collagenous elements), a macromolecular crowding-driven bioprinting technique that enables the immediate gelation of collagen bioinks infused with cells. This overcomes the need for extended incubation, allowing for direct bioprinting of engineered cardiac tissues with high fidelity. Unlike methods that rely on high-concentration acidic collagen or fibrin for gelation, TRACE achieves rapid bioink stabilization without altering the biochemical composition. This ensures greater versatility in bioink selection while maintaining functional tissue outcomes. Additionally, agarose slurry provides stable structural support, preventing tissue collapse while allowing nutrient diffusion. This approach better preserves complex tissue geometries during culture than gelatin-based support baths or polydimethylsiloxane (PDMS) molds. Our results demonstrate that TRACE enables the bioprinting of structurally stable cardiac tissues with high resolution. By supporting the fabrication of biomimetic tissues, TRACE represents a promising advancement in bioprinting cardiac models and other engineered tissues.
- 1 June 2025
- Published by AIP Publishing in APL Bioengineering
- Vol. 9 (2) , 026124
Open AccessApplication of instant assembly of collagen to bioprint cardiac tissues
Advancing cardiac tissue engineering requires innovative fabrication techniques, including 3D bioprinting and tissue maturation, to enable the generation of new muscle for repairing or replacing damaged heart tissue. Recent advances in tissue engineering have highlighted the need for rapid, high-resolution bioprinting methods that preserve cell viability and maintain structural fidelity. Traditional collagen-based bioinks gel slowly, limiting their use in bioprinting. Here, we implement TRACE (tunable rapid assembly of collagenous elements), a macromolecular crowding-driven bioprinting technique that enables the immediate gelation of collagen bioinks infused with cells. This overcomes the need for extended incubation, allowing for direct bioprinting of engineered cardiac tissues with high fidelity. Unlike methods that rely on high-concentration acidic collagen or fibrin for gelation, TRACE achieves rapid bioink stabilization without altering the biochemical composition. This ensures greater versatility in bioink selection while maintaining functional tissue outcomes. Additionally, agarose slurry provides stable structural support, preventing tissue collapse while allowing nutrient diffusion. This approach better preserves complex tissue geometries during culture than gelatin-based support baths or polydimethylsiloxane (PDMS) molds. Our results demonstrate that TRACE enables the bioprinting of structurally stable cardiac tissues with high resolution. By supporting the fabrication of biomimetic tissues, TRACE represents a promising advancement in bioprinting cardiac models and other engineered tissues.
- Open Access
- 23 April 2025
- Published by Springer Nature in Research Square
Atrial Fibrillation Induces Sarcomere Remodeling, Enhanced Sarcomere Contractility, and Loss of Atrial Identity
Atrial fibrillation (AF) is the most common arrhythmia, with few treatment options. To discover novel pathways, we performed mass spectrometry (MS) on atrial tissue from patients in Sinus Rhythm or with AF without heart failure. We identified changes in canonical AF pathways, although surprisingly, contractile proteins and specifically a loss of atrial isoforms. Functional remodeling was confirmed in AF cardiomyocytes, revealing increased contractility compared to SR. We performed MS analysis of human atrial and ventricular tissue and found that ~1/3 of proteomic remodeling in AF was associated with chamber identity. Using atrial hiPSC-CM Engineered Heart Tissues to model AF, we replicated proteomic and contractile remodeling observed in human tissue, indicating mechano-sensing likely drives these effects. Lastly, an integrative patient simulation suggests this cellular remodeling is likely maladaptive. Together, these results reveal a novel role for sarcomere remodeling and a loss of atrial identity in AF, representing potential new therapeutic targets.
- 23 April 2025
- Published by Springer Nature in Research Square
Open AccessAtrial Fibrillation Induces Sarcomere Remodeling, Enhanced Sarcomere Contractility, and Loss of Atrial Identity
Atrial fibrillation (AF) is the most common arrhythmia, with few treatment options. To discover novel pathways, we performed mass spectrometry (MS) on atrial tissue from patients in Sinus Rhythm or with AF without heart failure. We identified changes in canonical AF pathways, although surprisingly, contractile proteins and specifically a loss of atrial isoforms. Functional remodeling was confirmed in AF cardiomyocytes, revealing increased contractility compared to SR. We performed MS analysis of human atrial and ventricular tissue and found that ~1/3 of proteomic remodeling in AF was associated with chamber identity. Using atrial hiPSC-CM Engineered Heart Tissues to model AF, we replicated proteomic and contractile remodeling observed in human tissue, indicating mechano-sensing likely drives these effects. Lastly, an integrative patient simulation suggests this cellular remodeling is likely maladaptive. Together, these results reveal a novel role for sarcomere remodeling and a loss of atrial identity in AF, representing potential new therapeutic targets.
- 1 June 2024
- Published by AIP Publishing in Biophysics Reviews
- Vol. 5 (2) , 021308
Engineered heart tissue: Design considerations and the state of the art
Originally developed more than 20 years ago, engineered heart tissue (EHT) has become an important tool in cardiovascular research for applications such as disease modeling and drug screening. Innovations in biomaterials, stem cell biology, and bioengineering, among other fields, have enabled EHT technologies to recapitulate many aspects of cardiac physiology and pathophysiology. While initial EHT designs were inspired by the isolated-trabecula culture system, current designs encompass a variety of formats, each of which have unique strengths and limitations. In this review, we describe the most common EHT formats, and then systematically evaluate each aspect of their design, emphasizing the rational selection of components for each application.
- 1 June 2024
- Published by AIP Publishing in Biophysics Reviews
- Vol. 5 (2) , 021308
Engineered heart tissue: Design considerations and the state of the art
Originally developed more than 20 years ago, engineered heart tissue (EHT) has become an important tool in cardiovascular research for applications such as disease modeling and drug screening. Innovations in biomaterials, stem cell biology, and bioengineering, among other fields, have enabled EHT technologies to recapitulate many aspects of cardiac physiology and pathophysiology. While initial EHT designs were inspired by the isolated-trabecula culture system, current designs encompass a variety of formats, each of which have unique strengths and limitations. In this review, we describe the most common EHT formats, and then systematically evaluate each aspect of their design, emphasizing the rational selection of components for each application.
- Open Access
- 26 February 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (5) , 503
Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing
Cardiac troponin (Tn) plays a central role in the evaluation of patients with angina presenting with acute coronary syndrome. The advent of high-sensitivity assays has improved the analytic sensitivity and precision of serum Tn measurement, but this advancement has come at the cost of poorer specificity. The role of clinical judgment is of heightened importance because, more so than ever, the interpretation of serum Tn elevation hinges on the careful integration of findings from electrocardiographic, echocardiographic, physical exam, interview, and other imaging and laboratory data to formulate a weighted differential diagnosis. A thorough understanding of the epidemiology, mechanisms, and prognostic implications of Tn elevations in each cardiac and non-cardiac etiology allows the clinician to better distinguish between presentations of myocardial ischemia and myocardial injury—an important discernment to make, as the treatment of acute coronary syndrome is vastly different from the workup and management of myocardial injury and should be directed at the underlying cause.
- 26 February 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (5) , 503
Open AccessClinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing
Cardiac troponin (Tn) plays a central role in the evaluation of patients with angina presenting with acute coronary syndrome. The advent of high-sensitivity assays has improved the analytic sensitivity and precision of serum Tn measurement, but this advancement has come at the cost of poorer specificity. The role of clinical judgment is of heightened importance because, more so than ever, the interpretation of serum Tn elevation hinges on the careful integration of findings from electrocardiographic, echocardiographic, physical exam, interview, and other imaging and laboratory data to formulate a weighted differential diagnosis. A thorough understanding of the epidemiology, mechanisms, and prognostic implications of Tn elevations in each cardiac and non-cardiac etiology allows the clinician to better distinguish between presentations of myocardial ischemia and myocardial injury—an important discernment to make, as the treatment of acute coronary syndrome is vastly different from the workup and management of myocardial injury and should be directed at the underlying cause.
- Open Access
- 9 February 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (4) , 378
Clinical Biochemistry of Serum Troponin
Accurate measurement and interpretation of serum levels of troponin (Tn) is a central part of the clinical workup of a patient presenting with chest pain suspicious for acute coronary syndrome (ACS). Knowledge of the molecular characteristics of the troponin complex and test characteristics of troponin measurement assays allows for a deeper understanding of causes of false positive and false negative test results in myocardial injury. In this review, we discuss the molecular structure and functions of the constituent proteins of the troponin complex (TnT, TnC, and TnI); review the different isoforms of Tn and where they are from; survey the evolution of clinical Tn assays, ranging from first-generation to high-sensitivity (hs); provide a primer on statistical interpretation of assay results based on different clinical settings; and discuss potential causes of false results. We also summarize the advances in technologies that may lead to the development of future Tn assays, including the development of point of care assays and wearable Tn sensors for real-time continuous measurement.
- 9 February 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (4) , 378
Open AccessClinical Biochemistry of Serum Troponin
Accurate measurement and interpretation of serum levels of troponin (Tn) is a central part of the clinical workup of a patient presenting with chest pain suspicious for acute coronary syndrome (ACS). Knowledge of the molecular characteristics of the troponin complex and test characteristics of troponin measurement assays allows for a deeper understanding of causes of false positive and false negative test results in myocardial injury. In this review, we discuss the molecular structure and functions of the constituent proteins of the troponin complex (TnT, TnC, and TnI); review the different isoforms of Tn and where they are from; survey the evolution of clinical Tn assays, ranging from first-generation to high-sensitivity (hs); provide a primer on statistical interpretation of assay results based on different clinical settings; and discuss potential causes of false results. We also summarize the advances in technologies that may lead to the development of future Tn assays, including the development of point of care assays and wearable Tn sensors for real-time continuous measurement.
- 1 December 2023
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (6) , H1373-H1385
Chronic diastolic stretch unmasks conduction defects in an in vitro model of arrhythmogenic cardiomyopathy
We uncover a novel mechanotransductive mechanism that unmasks conduction defects in arrhythmogenic cardiomyopathy (ACM). Using a novel dynamic bioreactor and human-induced pluripotent stem cell (hiPSC)-derived engineered heart tissue (EHT), we apply strain at distinct intervals during the cardiac cycle. Imposing mechanical strain during diastole selectively slows conduction velocity. To our knowledge, this is the first time that the effect of mechanical loading during a specific part of the cardiac cycle has been shown to cause conduction deficits in ACM.
- 1 December 2023
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (6) , H1373-H1385
Chronic diastolic stretch unmasks conduction defects in an in vitro model of arrhythmogenic cardiomyopathy
We uncover a novel mechanotransductive mechanism that unmasks conduction defects in arrhythmogenic cardiomyopathy (ACM). Using a novel dynamic bioreactor and human-induced pluripotent stem cell (hiPSC)-derived engineered heart tissue (EHT), we apply strain at distinct intervals during the cardiac cycle. Imposing mechanical strain during diastole selectively slows conduction velocity. To our knowledge, this is the first time that the effect of mechanical loading during a specific part of the cardiac cycle has been shown to cause conduction deficits in ACM.
- Open Access
- 11 December 2013
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 45 (1) , 209
Corrigendum to 'The effect of combined hyperbaric oxygen and iloprost treatment on the prevention of spinal cord ischaemia-reperfusion injury: an experimental study' [Eur J Cardiothorac Surg 2013;44:e332-e340]
At the request of the authors, the author list in this article has been changed to the one stated above. The previous list included Hasan Gucer instead of Levent Tumkaya.
- 11 December 2013
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 45 (1) , 209
Open AccessCorrigendum to 'The effect of combined hyperbaric oxygen and iloprost treatment on the prevention of spinal cord ischaemia-reperfusion injury: an experimental study' [Eur J Cardiothorac Surg 2013;44:e332-e340]
At the request of the authors, the author list in this article has been changed to the one stated above. The previous list included Hasan Gucer instead of Levent Tumkaya.